U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 2

1.
Figure 2.

Figure 2. From: Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.

Overall and progression-free survival by Kaplan-Meier curves.

Vaishali Sanchorawala, et al. Haematologica. 2013 May;98(5):789-792.
2.
Figure 1

Figure 1. From: Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.

Toxicities, dose reductions and outcomes analysis by subject number. Chart A: Starts on right side with toxicities on x-axis and subject number on y-axis. #Subject; ψ: venous; *: acute. Chart B: Starts on bottom left corner with subject number on x-axis and duration of protocol-directed treatment on y-axis. Dose reductions are superimposed on individual time bars with outcome listed at the end.

Vaishali Sanchorawala, et al. Haematologica. 2013 May;98(5):789-792.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center